Vanda generated $57.2 million in total revenues in Q4 2025, up 8% year-over-year, driven by 25% growth in Fanapt sales. The company reported a net loss of $141.2 million, primarily due to a $113.7 million one-time non-cash tax charge.

Vanda Pharmaceuticals reported total net product sales of $50.0 million for the first quarter of 2025, a 5% increase from the previous year. The company experienced a net loss of $29.5 million, reflecting expenses related to a new license agreement and increased commercial activities. Fanapt showed significant growth with a 14% increase in total prescriptions and net product sales.

Vanda Pharmaceuticals Inc. announced robust financial and operational results for the fourth quarter and full year ended December 31, 2024. Total net product sales for Q4 2024 reached $53.2 million, a 17% increase year-over-year, primarily fueled by an 18% rise in Fanapt® net product sales. Despite a net loss of $4.9 million for the quarter, the company highlighted significant progress in its development pipeline, including multiple regulatory submissions and commercial launches, positioning it for continued growth in 2025 and beyond.

Vanda Pharmaceuticals reported Q3 2024 financial results, with revenues of $47.7 million, a 23% increase compared to Q3 2023. The company launched Fanapt® in bipolar I disorder and PONVORY® for multiple sclerosis. A net loss of $5.3 million was reported, and financial guidance for the full year 2024 was revised, raising the midpoint of revenue and cash ranges.

Vanda Pharmaceuticals reported a net loss of $4.5 million for Q2 2024, compared to a net income of $1.5 million in Q2 2023. However, total revenues increased by 10% to $50.5 million compared to Q2 2023.

Vanda Pharmaceuticals reported a total revenue of $47.5 million, a decrease of 24% compared to Q1 2023. Net loss was $4.1 million, compared to net income of $3.3 million in Q1 2023. Cash, cash equivalents and marketable securities was $394.1 million as of March 31, 2024, representing an increase to Cash of $5.9 million compared to December 31, 2023.

Vanda Pharmaceuticals reported a net loss of $2.4 million for Q4 2023, compared to a net income of $6.9 million in Q4 2022. Total revenues were $45.3 million, a 30% decrease from $64.5 million in Q4 2022, but a 17% increase compared to $38.8 million in Q3 2023. The company completed the acquisition of PONVORY® in Q4 2023 for $100 million.

Vanda Pharmaceuticals reported total net product sales of $38.8 million from HETLIOZ® and Fanapt® in Q3 2023, a 41% decrease compared to Q3 2022. Net income was $0.1 million, a decrease from $3.3 million in the same quarter of the previous year. The company is advancing its development pipeline and expects FDA decisions on two sNDAs in the first half of 2024.

Vanda Pharmaceuticals reported a total revenue of $46.1 million, driven by net product sales from HETLIOZ® and Fanapt®. Net income for the quarter was $1.5 million. The company is facing challenges with HETLIOZ® due to the at-risk launch of a generic version in the U.S.

Vanda Pharmaceuticals reported a total revenue of $62.5 million for Q1 2023, a 4% increase compared to Q1 2022. The company achieved a net income of $3.3 million, a significant improvement from the net loss of $6.4 million in the same period last year. Vanda is also preparing for multiple regulatory submissions.

Vanda Pharmaceuticals reported Q4 2022 total revenues of $64.5 million, a 5% decrease compared to Q4 2021. Net income was $6.9 million, slightly lower than the $7.1 million reported in the same quarter of the previous year. The company is pursuing regulatory approvals for HETLIOZ® and preparing for an NDA submission for tradipitant.

Vanda Pharmaceuticals reported a total revenue of $65.3 million and a net income of $3.3 million for Q3 2022. The company is focusing on commercial execution and pipeline advancement.

Vanda Pharmaceuticals reported Q2 2022 total revenues of $64.4 million, a 5% decrease compared to Q2 2021. Net income was $2.6 million, compared to $9.7 million in the same period last year.

Vanda Pharmaceuticals reported a decrease in total net product sales to $60.2 million, a 4% decrease compared to the first quarter of 2021. The company experienced a net loss of $6.4 million compared to a net income of $8.7 million in the same period last year.

Vanda Pharmaceuticals reported a 1% increase in total net product sales from HETLIOZ® and Fanapt®, reaching $68.0 million in Q4 2021, and a net income of $7.1 million compared to $8.2 million in Q4 2020.

Vanda Pharmaceuticals reported Q3 2021 total revenues of $70.1 million, a 16% increase compared to Q3 2020. The company is awaiting results from the Phase III study of tradipitant in gastroparesis expected by the end of 2021.

Vanda Pharmaceuticals reported Q2 2021 total revenues of $67.9 million, a 9% increase compared to Q2 2020. The company's income before taxes was $12.6 million, compared to $11.1 million in the second quarter of 2020.

Vanda Pharmaceuticals reported a total revenue of $62.7 million for Q1 2021, an 8% increase compared to Q1 2020. The company also reported a net income of $8.7 million, compared to $0.5 million in the first quarter of 2020.

Vanda Pharmaceuticals reported Q4 2020 total revenues of $67.7 million, an 11% increase compared to Q4 2019. Income before taxes was $10.9 million in the fourth quarter of 2020 compared to $5.8 million in the fourth quarter of 2019.

Vanda Pharmaceuticals reported a 1% increase in total net product sales for Q3 2020 compared to Q3 2019, with $60.3 million in sales. The company's income before taxes was $8.4 million, and net income was $5.9 million. The HETLIOZ® Smith-Magenis Syndrome marketing authorization applications were accepted by the FDA for priority review.

Vanda Pharmaceuticals reported a 5% increase in total revenues to $62.2 million for the second quarter of 2020, driven by record sales of HETLIOZ®. Net income was $8.7 million, compared to $11.5 million in the second quarter of 2019. The company's cash, cash equivalents, and marketable securities increased to $339.8 million.

Vanda Pharmaceuticals reported a strong first quarter in 2020, with a 22% increase in total revenues year-over-year, reaching $58.0 million. The company also achieved net income of $0.5 million, a significant improvement compared to the net loss of $0.6 million in the first quarter of 2019.

Vanda Pharmaceuticals Inc. announced its Q4 and full year 2019 financial results, with Q4 total revenues reaching $60.9 million, a 15% increase compared to the same period in 2018. The company reported a net income of $4.2 million for the quarter.